Glucose alone is not enough warning

Glucose is the everyday sugar number people with diabetes manage. Ketones are different. They rise when the body burns fat for energy without enough insulin — the path toward diabetic ketoacidosis (DKA), a serious emergency that can move in hours. A continuous glucose monitor watches sugar. It does not watch ketones. On 25 August 2026, the U.S. FDA authorized a dual biowearable class that can watch both in the background. That is the new fact. It is not a brand you must name. It is not a U.S. shelf date for every pharmacy that same week.

What happened

On 25 August 2026, Abbott announced FDA authorization of Libre Duo 10 Day — described as the world’s first dual glucose–ketone sensing biowearable. The path was Breakthrough Device designation, then De Novo authorization. Abbott says the system is the first to meet the FDA’s integrated continuous glucose monitoring (iCGM) standard and a new integrated continuous glucose and ketone monitoring (iCGK) standard.

The design intent is simple to restate: keep glucose visible for daily management, and watch ketones in the background so rising ketones can trigger an alert without a separate strip every time. Ages 2 and older. Up to about ten days of wear. It is meant to use the latest U.S. Libre app and the wider Libre digital ecosystem. Abbott plans a U.S. launch later in 2026. Libre Duo systems already had CE Mark earlier in 2026.

Keep the clocks apart. Breakthrough, CE, De Novo week, U.S. launch later, and later hooks into automated insulin delivery (AID) systems are not one event. Abbott says it is working with pump companies and expects some AID connections later in 2026 and others in 2027. Do not collapse those into “already on every pump.”

The one idea

Glucose alone is not enough warning. Ketones can rise while glucose looks fine. One wearable can now watch both in the background.

That is a capability class — dual continuous glucose–ketone sensing — not a homework assignment to name a brand. Learn the class. Leave the local use open.

Honest limits

• FDA De Novo authorization announced 25 August 2026. Sponsor: U.S. launch later in 2026 — not treated here as every shelf that same day.
• Ages 2+. Up to 10 days of wear; not every sensor lasts the full period (sponsor wear study).
• Ketone output is used with glucose. Alarms may miss some extremes. Labeling still asks for clinical judgment and fingerstick confirmation when readings disagree with symptoms (sponsor Important Safety Information).
• CGMs alone do not measure ketones. Separate strips are snapshots. That gap is the point of the class.
• CE Mark earlier in 2026 is not the same event as the U.S. De Novo week.
• AID integrations are expected later — not a same-week claim that every pump already talks to this sensor.
• This page is not medical advice. It teaches what the capability class can do and what it is not.
• Naming a brand is not the invention.

Sources

• Abbott media room, 25 August 2026: https://abbott.mediaroom.com/2026-08-25-Abbott-receives-FDA-authorization-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes
• Abbott Libre Duo page (company): https://abbo.tt/libreduo

Try inventing

Warmer Sun is where people come to follow, understand, and learn — not a lab. If you can restate the difference — glucose alone is not enough warning — you understand the week.

You can try inventing with this at https://warmersun.com/forge/?q=spotlight-iot-riverglen-duo-signal-2026. Free signup. No card.